As the market reaches new heights, investors are on the lookout for fresh opportunities beyond the familiar S&P index. We’ve compiled a list of top picks from analysts who have maintained a bullish stance over the past quarter, categorized by sector for easy navigation.
**Healthcare**
* Acrivon Therapeutics (ACRV): With a robust pipeline and strong cash reserves, this precision oncology player is poised for growth, according to Technical Titan.
* GRAIL, Inc. (GRAL): Mitchell Mauer sees significant potential in GRAIL’s cancer-screening test and restructuring efforts, which aim to cut costs and extend its cash runway.
* Corcept Therapeutics (CORT): Graham Tanaka highlights this profitable biotech company’s potential for revenue growth and expansion into new therapeutic areas.
**Finance**
* AGBA Group (AGBA): Manole Capital Management believes the merger with Triller will unlock capital-raising opportunities and synergies, presenting a significant upside.
* SLR Investment (SLRC): Allen Cooke notes that this business development company is trading at a 15% discount to net asset value, offering a 10.6% yield and diversified portfolio.
**Financial Services**
* T. Rowe Price (TROW): Jonathan Yates recommends this dividend aristocrat, boasting a 4.7% yield and a strong track record of stability and growth.
Leave a Reply